NCT01527708

Brief Summary

Primary objective of this study was to assess the intrasession, intersession and interobserver variability of the Pentacam-derived curvature and zernike coefficients in back surface of normal, keratoconic and crosslinked corneas.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
129

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Sep 2011

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2011

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2011

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

February 3, 2012

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 7, 2012

Completed
Last Updated

February 7, 2012

Status Verified

January 1, 2012

Enrollment Period

2 months

First QC Date

February 3, 2012

Last Update Submit

February 3, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Variability of posterior corneal surface curvature and aberrometric measurements within and between sessions and within and between observers.

    The Pentacam Classic (Oculus Optikgerate GmbH, Heidelberg, Germany, software version 1.14r04) was used for the sake of the study. Three consecutive scans were obtained by two experienced operators for the assessment of intrasession and interobserver variability. The same procedure was repeated within two weeks for the assessment of intersession variability.Bland-Altman plots were used to evaluate agreement between the 2 operators. The reliability of all measurements was evaluated by means of the intraclass correlation coefficient(ICC).

    2 weeks

Study Arms (3)

Keratoconus Group (KCG)

Keratoconus group (KCG) included patients with progressive keratoconus.

Collagen-Cross-linking group (CXLG)

Collagen-Cross-linking group (CXLG) included keratoconus patients that had been treated with uneventful corneal collagen cross-linking (CXL) at least on year prior to their enrolment in the study.

Procedure: Corneal Collagen Cross-linking (CXL)

Normal Group (NG)

Normal group (NG) was formed by refractive surgery candidates who visited EIT's refractive surgery service for their preoperative examination. Eligibility for participation in the NG was confirmed by consecutive topographies, while all NG participants had to present uneventful ophthalmologic history, no indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography.

Interventions

Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.

Collagen-Cross-linking group (CXLG)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Participants were recruited from the Cornea service of the EIT in a consecutive-if-eligible basis.

You may qualify if:

  • Ideal refractive surgery candidate (Normal Group)
  • Progressive keratoconus (Keratoconus group)
  • Corneal collagen cross linking (CxL) treatment at least one year prior to enrollment (CxL group)

You may not qualify if:

  • (Normal Group)
  • No indications of corneal pathology in slit-lamp biomicroscopy and Placido disk-based videokeratography
  • Uneventful ophthalmologic history
  • All groups:
  • Glaucoma
  • Suspicion of glaucoma
  • history of herpetic keratitis
  • corneal scarring
  • severe eye dryness
  • pregnancy or nursing
  • current corneal infection
  • underlying autoimmune disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Eye Institute of Thrace (EIT)

Alexandroupoli, Thrace, 68100, Greece

Location

MeSH Terms

Conditions

Keratoconus

Interventions

Corneal Cross-Linking

Condition Hierarchy (Ancestors)

Corneal DiseasesEye Diseases

Intervention Hierarchy (Ancestors)

PhotochemotherapyCombined Modality TherapyTherapeuticsDrug TherapyPhototherapy

Study Officials

  • Georgios Labiris, Lecturer

    Democritus University of Thrace

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Lecturer

Study Record Dates

First Submitted

February 3, 2012

First Posted

February 7, 2012

Study Start

September 1, 2011

Primary Completion

November 1, 2011

Study Completion

December 1, 2011

Last Updated

February 7, 2012

Record last verified: 2012-01

Locations